Literature DB >> 22348606

Comparative study of regulatory T cells expanded ex vivo from cord blood and adult peripheral blood.

Huahua Fan1, Jie Yang, Jun Hao, Yana Ren, Liang Chen, Guiping Li, Rufeng Xie, Yiming Yang, Feng Gao, Mingyao Liu.   

Abstract

In this study, we expanded regulatory T cells (Tregs) ex vivo from CD4(+) CD25(+) T cells from cord blood (CB) and CD4(+) CD25(+) CD127(-) T cells from adult peripheral blood (APB) and compared the suppressive functions of the newly generated Tregs. The Tregs from CB and APB were expanded either in two cycles with a polyclonal stimulus or in two cycles with an alloantigen stimulus in the first cycle and a polyclonal stimulus in the second cycle. Cell yield after Treg expansion with polyclonal stimulation was greater than that of Tregs expanded with combined alloantigen and polyclonal stimulation. The expanded Tregs expressed high levels of Foxp3, CD39 and cytotoxic T-lymphocyte antigen-4 and low levels of CD127, interleukin-2 and interferon-γ. After two cycles of expansion, the CB Tregs maintained expression of the GARP gene and showed greater suppressive function than APB Tregs. The CB Tregs that were expanded with two cycles of polyclonal stimulation suppressed not only the polyclonal antigen-driven responder T (T(resp)) cell proliferation but also the HLA mismatched dendritic cell-driven T(resp) cell proliferation. When CB and APB Tregs were expanded with a primary alloantigen stimulus followed by a secondary polyclonal stimulus, the Tregs showed a potent, antigen-specific suppressive capacity. The Tregs expanded with two cycles of polyclonal stimulation from both CB and APB alleviated acute graft-versus-host disease symptoms and prolonged survival in a murine model of graft-versus-host disease. In conclusion, CB Tregs expanded with two cycles of polyclonal stimulation had a stronger immunosuppressive function than APB Tregs. It is feasible to obtain human functional alloantigen-specific Tregs expanded ex vivo from CB and APB in large numbers.
© 2012 The Authors. Immunology © 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22348606      PMCID: PMC3403260          DOI: 10.1111/j.1365-2567.2012.03573.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  33 in total

1.  In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures.

Authors:  Wayne R Godfrey; Ying G Ge; Darrin J Spoden; Bruce L Levine; Carl H June; Bruce R Blazar; Stephen B Porter
Journal:  Blood       Date:  2004-03-18       Impact factor: 22.113

Review 2.  Modulation of graft-versus-host disease: role of regulatory T lymphocytes.

Authors:  Allan D Hess
Journal:  Biol Blood Marrow Transplant       Date:  2006-01       Impact factor: 5.742

3.  The generation of CD25+ CD4+ regulatory T cells that prevent allograft rejection does not compromise immunity to a viral pathogen.

Authors:  Andrew Bushell; Emma Jones; Awen Gallimore; Kathryn Wood
Journal:  J Immunol       Date:  2005-03-15       Impact factor: 5.422

4.  Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice.

Authors:  Emma L Masteller; Matthew R Warner; Qizhi Tang; Kristin V Tarbell; Hugh McDevitt; Jeffrey A Bluestone
Journal:  J Immunol       Date:  2005-09-01       Impact factor: 5.422

Review 5.  CD4+CD25+ regulatory T cells and graft-versus-host disease.

Authors:  Petra Hoffmann; Matthias Edinger
Journal:  Semin Hematol       Date:  2006-01       Impact factor: 3.851

6.  An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin.

Authors:  K R Cooke; L Kobzik; T R Martin; J Brewer; J Delmonte; J M Crawford; J L Ferrara
Journal:  Blood       Date:  1996-10-15       Impact factor: 22.113

7.  Isolation of CD4+CD25+ regulatory T cells for clinical trials.

Authors:  Petra Hoffmann; Tina J Boeld; Ruediger Eder; Julia Albrecht; Kristina Doser; Biserka Piseshka; Ashraf Dada; Claudia Niemand; Mario Assenmacher; Evelyn Orsó; Reinhard Andreesen; Ernst Holler; Matthias Edinger
Journal:  Biol Blood Marrow Transplant       Date:  2006-03       Impact factor: 5.742

8.  Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia.

Authors:  Aurélie Trenado; Frédéric Charlotte; Sylvain Fisson; Micael Yagello; David Klatzmann; Benoit L Salomon; José L Cohen
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

9.  Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation.

Authors:  Jie Yang; Li Gao; Yan Liu; Yana Ren; Rufeng Xie; Huahua Fan; Kaicheng Qian
Journal:  Transfusion       Date:  2009-09-24       Impact factor: 3.157

10.  In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes.

Authors:  Qizhi Tang; Kammi J Henriksen; Mingying Bi; Erik B Finger; Greg Szot; Jianqin Ye; Emma L Masteller; Hugh McDevitt; Mark Bonyhadi; Jeffrey A Bluestone
Journal:  J Exp Med       Date:  2004-06-07       Impact factor: 14.307

View more
  16 in total

1.  Maturation of CD4+ regulatory T lymphocytes and of cytokine secretions in infants born prematurely.

Authors:  V Dirix; F Vermeulen; F Mascart
Journal:  J Clin Immunol       Date:  2013-06-21       Impact factor: 8.317

2.  HIV, Cytomegalovirus, and Malaria Infections during Pregnancy Lead to Inflammation and Shifts in Memory B Cell Subsets in Kenyan Neonates.

Authors:  Kee Thai Yeo; Paula Embury; Timothy Anderson; Peter Mungai; Indu Malhotra; Christopher King; James Kazura; Arlene Dent
Journal:  J Immunol       Date:  2019-01-23       Impact factor: 5.422

Review 3.  Autologous regulatory T cells for the treatment of type 1 diabetes.

Authors:  James A Thompson; Daniel Perry; Todd M Brusko
Journal:  Curr Diab Rep       Date:  2012-10       Impact factor: 4.810

4.  Effect of chorioamnionitis on regulatory T cells in moderate/late preterm neonates.

Authors:  Cesar M Rueda; Casey B Wells; Tate Gisslen; Alan H Jobe; Suhas G Kallapur; Claire A Chougnet
Journal:  Hum Immunol       Date:  2014-11-08       Impact factor: 2.850

5.  Lysosomal-associated Transmembrane Protein 4B (LAPTM4B) Decreases Transforming Growth Factor β1 (TGF-β1) Production in Human Regulatory T Cells.

Authors:  Caroline Huygens; Stéphanie Liénart; Olivier Dedobbeleer; Julie Stockis; Emilie Gauthy; Pierre G Coulie; Sophie Lucas
Journal:  J Biol Chem       Date:  2015-06-30       Impact factor: 5.157

6.  Large-scale in vitro expansion of human regulatory T cells with potent xenoantigen-specific suppression.

Authors:  Xi Jin; Yanrong Lu; Ye Zhao; Shounan Yi
Journal:  Cytotechnology       Date:  2015-01-22       Impact factor: 2.058

7.  Enhancing and stabilization of cord blood regulatory T-cell suppressive function by human mesenchymal stem cell (MSC)-derived exosomes.

Authors:  Juan Zhang; Xiaoqian Ma; Lu Cao; Xing He; Sang Li; Min Yang; Cejun Yang; Pengfei Rong; Shounan Yi; Kedar Ghimire; Xiangfeng Kong; Wei Wang
Journal:  Clin Exp Immunol       Date:  2022-06-23       Impact factor: 5.732

8.  Expression and significance of CD4(+)CD25(+)CD127(-) regulatory T cells in peripheral blood of patients with different phenotypes of Guillain-Barré syndrome.

Authors:  Hao Wang; Li Li; Yin Zhang; Shu-Chao Pan; An-Qiang Chen; Wei-Dong Qian
Journal:  Int J Clin Exp Med       Date:  2015-10-15

9.  Differentiated Cells Derived from Hematopoietic Stem Cells and Their Applications in Translational Medicine.

Authors:  Sophia S Fernandes; Lalita S Limaye; Vaijayanti P Kale
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

10.  Multiple unit pooled umbilical cord blood is a viable source of therapeutic regulatory T cells.

Authors:  Kate Milward; Fadi Issa; Joanna Hester; Daniel Figueroa-Tentori; Alejandro Madrigal; Kathryn J Wood
Journal:  Transplantation       Date:  2013-01-15       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.